Bone Mineral Density After Transitioning From Denosumab to Alendronate

CONTEXT: There are few studies on patients transitioning from denosumab to bisphosphonates. OBJECTIVE: To investigate patient characteristics and changes in bone mineral density (BMD) after transitioning from denosumab to alendronate. DESIGN: Randomized, open-label, 2-year crossover Denosumab Adhere...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Endocrinol Metab
Main Authors: Kendler, David, Chines, Arkadi, Clark, Patricia, Ebeling, Peter R, McClung, Michael, Rhee, Yumie, Huang, Shuang, Stad, Robert Kees
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2019
Assuntos:
Online Only
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7112973/
https://ncbi.nlm.nih.gov/pubmed/31665314
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/clinem/dgz095
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares